Marixino (Memantine Hydrochloride)

Memantine acts as a non‑competitive antagonist at NMDA receptors, blocking excessive calcium influx caused by overstimulation of glutamate. This reduces excitotoxic neuronal damage, helping to preserve neuronal function and slow cognitive decline associated with Alzheimer’s disease.

The specific dose of Marixino is determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Dosage adjustments are made individually; patients should follow the prescriber’s instructions exactly.

Safety data for memantine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss risks with their healthcare provider.

To request Marixino, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Marixino (memantine) belongs to the NMDA receptor antagonist class, differing from acetylcholinesterase inhibitors such as donepezil. While both improve cognition, memantine targets glutamatergic excitotoxicity, often used in moderate disease stages, and may be combined with an acetylcholinesterase inhibitor for additive benefit.

Marixino should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, heat, and direct sunlight to maintain stability and potency throughout its shelf life.

Marixino is taken orally, usually once daily after a titration period. The tablet should be swallowed whole with water and not crushed or chewed, unless otherwise directed by a healthcare professional.

Serious risks, though rare, include severe skin reactions such as Stevens‑Johnson syndrome, hypersensitivity reactions, seizures, and neuropsychiatric events like hallucinations. Patients should seek immediate medical attention if they experience rash, swelling, seizure activity, or significant changes in mental status.

Marixino is contraindicated in patients with known hypersensitivity to memantine or any component of the formulation. Caution is advised for individuals with severe renal impairment, uncontrolled seizures, or those taking other NMDA antagonists, as these conditions increase the risk of adverse effects.